Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
21.54
-0.84 (-3.75%)
Feb 21, 2025, 4:00 PM EST - Market closed
Cidara Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Cidara Therapeutics stock have an average target of 32.2, with a low estimate of 24 and a high estimate of 45. The average target predicts an increase of 49.49% from the current stock price of 21.54.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 13, 2024.
Analyst Ratings
The average analyst rating for Cidara Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 27, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $34 | Buy | Initiates | $34 | +57.85% | Dec 13, 2024 |
| WBB Securities | WBB Securities | Strong Buy Maintains $40 → $45 | Strong Buy | Maintains | $40 → $45 | +108.91% | Dec 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +11.42% | Nov 11, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +53.20% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
7.03M
from 23.28M
Decreased by -69.81%
Revenue Next Year
n/a
from 7.03M
EPS This Year
-24.65
from -5.25
EPS Next Year
-9.78
from -24.65
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 10.5M | n/a | n/a | |||
| Avg | 7.0M | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -54.9% | - | - | |||
| Avg | -69.8% | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -19.83 | -5.04 | -3.74 | |||
| Avg | -24.65 | -9.78 | -9.69 | |||
| Low | -29.37 | -16.42 | -18.06 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.